Amyloid and lipids in the pathology of Alzheimer disease.

In the last decade, we have witnessed an avalanche of information about the morphological and biochemical changes that occur in Alzheimer disease (AD). This knowledge has provided new strategies for treatment and identified possible approaches for prevention. Because AD pathology is relentlessly progressive, occurring over years or decades, successful treatment will depend on early intervention and therefore recognition of risk factors that lead to the development of this dementia. In the present review, we advance some of the alterations of lipid and membrane metabolism, alone or in association with β-amyloid peptide (AP), as pivotal components of AD pathophysiology. At present, the 40 and 42 amino acid long Aβ, resulting from the intracellular proteolytic processing of the β-amyloid precursor protein (AβPP), have deservedly taken center stage in investigations throughout the world. Fibrillar Aβ42 and Aβ40 are preferentially deposited in neuritic plaques1 and in vascular walls2, respectively. In a very l...

[1]  Steven G. Clarke,et al.  Role of ERAB/l-3-Hydroxyacyl-coenzyme A Dehydrogenase Type II Activity in Aβ-induced Cytotoxicity* , 1999, The Journal of Biological Chemistry.

[2]  P. Greengard,et al.  Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Gandy,et al.  Involvement of Cell Surface Glycosyl-phosphatidylinositol-linked Aspartyl Proteases in α-Secretase-type Cleavage and Ectodomain Solubilization of Human Alzheimer β-Amyloid Precursor Protein in Yeast* , 1998, The Journal of Biological Chemistry.

[4]  M. Emmerling,et al.  Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. , 1998, Biochemical and biophysical research communications.

[5]  D. Peterson,et al.  Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Mizuno,et al.  Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells. , 1998, Biochimica et biophysica acta.

[7]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[8]  B. Greenberg,et al.  Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol* , 1998, The Journal of Biological Chemistry.

[9]  Y. Luo,et al.  Amyloid Precursor Protein Processing in Sterol Regulatory Element-binding Protein Site 2 Protease-deficient Chinese Hamster Ovary Cells* , 1998, The Journal of Biological Chemistry.

[10]  H. Soininen,et al.  Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism , 1998, Journal of neurology, neurosurgery, and psychiatry.

[11]  K Namekata,et al.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. , 1998, The American journal of pathology.

[12]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Paganetti,et al.  Lack of β‐amyloid production in M19 cells deficient in site 2 processing of the sterol regulatory element binding proteins , 1998, FEBS letters.

[14]  A. von Eckardstein,et al.  Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. , 1998, The Journal of clinical investigation.

[15]  J. Poirier,et al.  β‐Amyloid Peptides Increase the Binding and Internalization of Apolipoprotein E to Hippocampal Neurons , 1998, Journal of neurochemistry.

[16]  B T Hyman,et al.  Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels , 1998, Journal of neuropathology and experimental neurology.

[17]  T. Kodama,et al.  βAPP γ‐secretase and SREBP site 2 protease are two different enzymes , 1998 .

[18]  S. DeKosky,et al.  Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene , 1998, Neuroscience Letters.

[19]  Y. Ihara,et al.  GM1 Ganglioside-Bound Amyloid β-Protein in Alzheimer’s Disease Brain , 1998, Neurobiology of Aging.

[20]  J. Seelig,et al.  Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. , 1997, Biochemistry.

[21]  M. T. Hasan,et al.  Complementation cloning of S2P, a gene encoding a putative metalloprotease required for intramembrane cleavage of SREBPs. , 1997, Molecular cell.

[22]  B. Permanne,et al.  Detection of apolipoprotein E/dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. , 1997, Biochemical and biophysical research communications.

[23]  E. Matsubara,et al.  Isoform‐Specific Effects of Apolipoproteins E2, E3, and E4 on Cerebral Capillary Sequestration and Blood‐Brain Barrier Transport of Circulating Alzheimer's Amyloid β , 1997, Journal of neurochemistry.

[24]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[25]  Xi Chen,et al.  An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.

[26]  L. Mucke,et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.

[27]  B. Hyman,et al.  Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. , 1997, Archives of neurology.

[28]  R. Duara,et al.  No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample , 1997, Neuroscience Letters.

[29]  L. Choo-Smith,et al.  Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1–40) Peptide to Ganglioside-containing Membrane Vesicles* , 1997, The Journal of Biological Chemistry.

[30]  W. D. Ehmann,et al.  Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease , 1997, Neurobiology of Aging.

[31]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.

[32]  L. Fenart,et al.  A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier , 1997, The Journal of cell biology.

[33]  Daniel Steinberg,et al.  Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.

[34]  D. D'urso,et al.  Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[35]  Z. Janka,et al.  Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease , 1997, Neuroscience Letters.

[36]  M. Mattson,et al.  4‐Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule‐associated protein tau , 1997, Neuroreport.

[37]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[38]  L. Thal,et al.  Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease , 1997, Neurology.

[39]  M. Sugawa,et al.  Oxidized low density lipoprotein caused CNS neuron cell death , 1997, Brain Research.

[40]  D. Wilson,et al.  Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. , 1997, The American journal of pathology.

[41]  M. Shapiro,et al.  Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein , 1997, Nature.

[42]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[43]  S. Birge The role of estrogen in the treatment of Alzheimer's disease , 1997, Neurology.

[44]  P. Greengard,et al.  Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Commenges,et al.  Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. , 1997, Revue neurologique.

[46]  P. Ianna,et al.  Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. , 1997, The Biochemical journal.

[47]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[48]  A. Hofman,et al.  Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.

[49]  T. Hashimoto,et al.  Cloning and expression of cDNA for a newly identified isozyme of bovine liver 3-hydroxyacyl-CoA dehydrogenase and its import into mitochondria. , 1997, Biochimica et biophysica acta.

[50]  T. Lehtimäki,et al.  Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains , 1997, Neurobiology of Aging.

[51]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[52]  S. Tsuji,et al.  Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's disease , 1997, Brain Research.

[53]  N. Craddock,et al.  Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population , 1997, Neuroscience Letters.

[54]  T. Montine,et al.  Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. , 1997, The American journal of pathology.

[55]  A Hofman,et al.  Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. , 1997, Stroke.

[56]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[57]  D. Mann,et al.  Preferential deposition of amyloid β protein (Aβ) in the form Aβ 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele , 1997, Neuroscience Letters.

[58]  A. Nordberg,et al.  Application of PET in dementia disorders , 1996, Acta neurologica Scandinavica. Supplementum.

[59]  R. Brasseur,et al.  Fusogenic Properties of the C-terminal Domain of the Alzheimer β-Amyloid Peptide* , 1996, The Journal of Biological Chemistry.

[60]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  J. Bailey,et al.  Isolation, mapping, and genomic structure of an X-linked gene for a subunit of human mitochondrial complex I. , 1996, Genomics.

[62]  A. Koudinov,et al.  Multiple inhibitory effects of Alzheimer's peptide Aβ1–40 on lipid biosynthesis in cultured human HepG2 cells , 1996, FEBS letters.

[63]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[64]  F. LaFerla,et al.  Extracellular deposition of beta-amyloid upon p53-dependent neuronal cell death in transgenic mice. , 1996, The Journal of clinical investigation.

[65]  A. Roher,et al.  Specific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia , 1996, The Journal of Neuroscience.

[66]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[67]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[68]  C. Gottfries,et al.  Membrane Components Separate Early-Onset Alzheimer's Disease From Senile Dementia of the Alzheimer Type , 1996, International Psychogeriatrics.

[69]  F. Maxfield,et al.  Microglial Cells Internalize Aggregates of the Alzheimer's Disease Amyloid β-Protein Via a Scavenger Receptor , 1996, Neuron.

[70]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[71]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[72]  W. Goux,et al.  Characterization of the Glycolipid Associated with Alzheimer Paired Helical Filaments , 1996, Journal of neurochemistry.

[73]  X. Hua,et al.  Sterol-Regulated Release of SREBP-2 from Cell Membranes Requires Two Sequential Cleavages, One Within a Transmembrane Segment , 1996, Cell.

[74]  R. Beavis,et al.  Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. , 1996, Biochemical and biophysical research communications.

[75]  R N Kalaria,et al.  Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. , 1996, The American journal of pathology.

[76]  D. Selkoe,et al.  Antibodies to amyloid β protein (Aβ) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) , 1996, Neurobiology of Aging.

[77]  X. Hua,et al.  Regulated Cleavage of Sterol Regulatory Element Binding Proteins Requires Sequences on Both Sides of the Endoplasmic Reticulum Membrane (*) , 1996, The Journal of Biological Chemistry.

[78]  T. Berezov,et al.  Alzheimer's peptides A beta 1-40 and A beta 1-28 inhibit the plasma cholesterol esterification rate. , 1996, Biochemistry and molecular biology international.

[79]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[80]  M. Gearing,et al.  Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's disease , 1996 .

[81]  W. Klein,et al.  Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.

[82]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[83]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[84]  K. Hamilton,et al.  Immunoreactivity for apolipoprotein A-IV in tanycytes and astrocytes of rat brain , 1995, Neuroscience Letters.

[85]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[86]  B. Hyman,et al.  Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy , 1995 .

[87]  D. Sparks,et al.  Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension , 1995, Journal of the Neurological Sciences.

[88]  P. Moran,et al.  Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[89]  W. Goux,et al.  Analysis of the core components of Alzheimer paired helical filaments A gas chromatography/mass spectrometry characterization of fatty acids, carbohydrates and long‐chain bases , 1995, FEBS letters.

[90]  E M Wijsman,et al.  Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.

[91]  L. Higgins,et al.  Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. Joseph,et al.  Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging , 1995, Trends in Neurosciences.

[93]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[94]  Y. Ihara,et al.  Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. , 1994, The Journal of biological chemistry.

[95]  P. Matsudaira,et al.  Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. , 1994, The Journal of biological chemistry.

[96]  C. Gottfries,et al.  Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II) , 1994, Journal of neurochemistry.

[97]  Stephen W. Scheff,et al.  Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.

[98]  A. Lacko,et al.  Plasma lipids and cholesterol esterification in Alzheimer's disease , 1994, Mechanisms of Ageing and Development.

[99]  M J Ball,et al.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[100]  M. Ball,et al.  Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue , 1993, Journal of neurochemistry.

[101]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[102]  L. Herbette,et al.  X‐Ray Diffraction Analysis of Brain Lipid Membrane Structure in Alzheimer's Disease and β‐Amyloid Peptide Interactions a , 1993, Annals of the New York Academy of Sciences.

[103]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[104]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[105]  S. Sisodia Beta-amyloid precursor protein cleavage by a membrane-bound protease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[106]  C. White,et al.  Alzheimer disease paired helical filament core structures contain glycolipid. , 1991, Biochemical and biophysical research communications.

[107]  D. Graham,et al.  βA4 amyloid protein deposition in brain after head trauma , 1991, The Lancet.

[108]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[109]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[110]  K. Tanaka,et al.  "Secretase," Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. , 1991, Biochemical and biophysical research communications.

[111]  D. Sparks,et al.  Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease , 1990, Neurobiology of Aging.

[112]  G. Lenzi,et al.  Serum lipoprotein pattern variations in dementia and ischemic stroke , 1990, Acta neurologica Scandinavica.

[113]  A. Wallin,et al.  Decreased myelin lipids in Alzheimer's disease and vascular dementia , 1989, Acta neurologica Scandinavica.

[114]  K. Horiuchi,et al.  Structure and expression of mouse apolipoprotein E gene. , 1989, Journal of biochemistry.

[115]  M. Paula-Barbosa,et al.  ALZHEIMER'S DISEASE: PAIRED HELICAL FILAMENTS AND CYTOMEMBRANES , 1987, Neuropathology and applied neurobiology.

[116]  T. Sunderland,et al.  Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. , 1999, The American journal of psychiatry.

[117]  J. Morris,et al.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.

[118]  E. Feskens,et al.  Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. , 1997, American journal of epidemiology.

[119]  W. Grant Dietary Links to Alzheimer's Disease , 1997 .

[120]  H. Wiśniewski,et al.  Beta-protein immunoreactivity in the human brain after cardiac arrest. , 1996, Folia neuropathologica.

[121]  T. Okumura,et al.  Apolipoprotein A-IV acts in the brain to inhibit gastric emptying in the rat. , 1996, The American journal of physiology.

[122]  T. Scott,et al.  Severe cardiovascular disease and Alzheimer's disease: Senile plaque formation in cortical areas , 1996, Clinical anatomy.

[123]  C. Bieberich,et al.  The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice , 1995, Nature Genetics.

[124]  D. Selkoe,et al.  Normal and abnormal biology of the beta-amyloid precursor protein. , 1994, Annual review of neuroscience.

[125]  J. Miller,et al.  Amino acid sequence of rabbit apolipoprotein E. , 1991, Journal of lipid research.

[126]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.